Funds to support clinical development of APX001, compound with novel mechanism to treat life-threatening fungal infections SAN DIEGO – August 2, 2017 – Amplyx Pharmaceuticals, a company developing novel antifungal agents for life-threatening fungal infections, today announced that it has raised $67 million through a Series C financing
Seattle, WA – May 15, 2017 – Genoa Pharmaceuticals, Inc., a biopharmaceutical company focused on development of improved therapies for idiopathic pulmonary fibrosis (IPF) and other severe pulmonary indications, today announced the completion of a $62 million Series A financing.
Tryton stent is the first dedicated bifurcation device to receive regulatory approval in the U.S. Cordis to be exclusive U.S. distributor of the Tryton stent. DURHAM, N.C.–(BUSINESS WIRE)–March 6, 2017–Tryton Medical, Inc., the leading developer of stents designed to treat coronary bifurcation lesions, today announced the U.S. Food and Drug Administration (FDA) has approved the […]
SAN DIEGO – January 05, 2017 – Amplyx Pharmaceuticals, a company developing novel antifungal agents for life-threatening fungal infections, today announced the appointments of Ciara Kennedy, Ph.D. to President and Chief Executive Officer (CEO) and Karen Joy Shaw, Ph.D., to Chief Scientific Officer (CSO). In conjunction with this announcement, the company’s former President and CEO, […]
By: David Nicklaus Source: St. Louis Post-Dispatch Date: December 2, 2016 When RiverVest Venture Partners opened its doors in 2000, hopes were high that it would be an important funding source for St. Louis’ nascent biotechnology industry. RiverVest went on to be a highly successful venture capital firm, managing $290 million and demonstrating a knack […]
ST. LOUIS, MO (Nov. 30, 2016) – Life sciences venture capital firm RiverVest Venture Partners today announced the closing of Archer Seed Fund, L.P. at $15 million.
SAN DIEGO – November 16, 2016 – Amplyx Pharmaceuticals, a company developing novel antifungal agents for life-threatening fungal infections, announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Product Development has granted orphan drug designation to APX001, the company’s lead drug candidate.
Long-term collaboration for US distribution of Tryton Side Branch Stent pending regulatory approval. DURHAM, NC – October 27, 2016 – Tryton Medical, Inc., the leading developer of stents designed to treat coronary bifurcation lesions, and Cardinal Health, a global integrated healthcare services and products company, today announced that the companies have established a long-term strategic […]
Preclinical Data from Multiple Models of Fibrosis and Collagen Deposition Presented at 1st International Conference on Tissue Repair, Regeneration, and Fibrosis SAN CARLOS, Calif., September 26, 2016 – New preclinical research presented by Allakos, Inc., shows the potential of the company’s recombinant antibodies to Siglec-8, an inhibitory receptor selectively expressed on the immune system’s mast […]
ST. LOUIS, MO (Sept. 16, 2016) – Tioma Therapeutics, Inc., a RiverVest portfolio company developing therapies to treat solid and blood-based cancers, announced it has raised $86 million in Series A venture financing. The Series A financing included early investor RiverVest along with Novo Ventures, GlaxoSmithKline’s corporate venture arm S.R. One, Limited and new investors, Roche […]
Cleveland, OH, September. 15, 2016 — Securus Medical Group, Inc., a privately held medical device company, announced the closing of a $10 million Series C financing led by Boston Scientific Corporation. Boston Scientific joined with existing investors RiverVest Venture Partners, 3X5 Special Opportunity Fund, and the University of Michigan MINTS program, as well as another […]
SAN DIEGO, Sept. 12, 2016 /PRNewswire/ — Amplyx Pharmaceuticals today announced the initiation of dosing in a Phase 1 clinical trial of APX001 in healthy volunteers. The randomized, double-blind, placebo-controlled, dose-escalation study will enroll approximately 80 healthy subjects. Intravenous infusion of APX001 will be administered as a single or multiple consecutive doses to healthy subjects. […]